Amneal Pharmaceuticals, Inc.· AMRX
🇺🇸 US · MidSP600NASDAQ
- Price
- $18.48
- Day
- -1.96%
- Mkt Cap
- $5.90B
- 52W Range
- $7.98 – $19.26
- Volume
- 2.07M
- Beta
- 1.26
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 335,098 shares of the company's stock, valued at approximately $4,165,000. Arkadios Wealth Advisors owned approximately
Read full article
Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.
Read full article
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Read full article
– Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost –
Read full article
Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.
Read full article
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago.
Read full article
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders. The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor.
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vial. Amneal plans to launch these products in the third quarter of 2026.
Read full article